Johnson & Johnson CEO Alex Gorsky says he’s receptive to change in how drugs are priced, but added that breakthrough drugs justify high prices.
“Obviously you’ve got to work with payers, providers,” Gorsky tells Fortune. “You’ve got to work with the government to make sure that’s done in a responsible way.”
The executive warned against dramatic shifts in the pricing landscape, however, suggesting that too many big changes could have unforeseen ramifications.
“I think (what) we need to be thoughtful about is making wholesale changes to the system that could have untoward consequences that ultimately restricts patients access to those kinds of products or actually is a disincentive to continue research that’s going to produce that next breakthrough.”